1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Topics

Showing 234 results for "Multiple Myeloma (MM)".

Thumbnail for AI-Assisted Simplification of Clinic Notes for Patients With Plasma Cell Dyscrasias and Myeloid Neoplasms to Improve Patient Understanding and Satisfaction: A Prospective Pilot Study

MM - 116

AI-Assisted Simplification of Clinic Notes for Patients With Plasma Cell Dyscrasias and Myeloid Neoplasms to Improve Patient Understanding and Satisfaction: A Prospective Pilot Study

Karun Neupane

Poster Presenter: Karun Neupane

$Thumbnail for Belantamab mafodotin (belamaf), bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: updated 4-year results of the phase 3 DREAMM-7 trial$

MM - 1168

Belantamab mafodotin (belamaf), bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: updated 4-year results of the phase 3 DREAMM-7 trial

Robert Rifkin

Poster Presenter: Robert Rifkin

SOHO 2026 Annual Meeting

Topics

AI-Assisted Simplification of Clinic Notes for Patients With Plasma Cell Dyscrasias and Myeloid Neoplasms to Improve Patient Understanding and Satisfaction: A Prospective Pilot Study

Belantamab mafodotin (belamaf), bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma: updated 4-year results of the phase 3 DREAMM-7 trial

Novel Interventions for Gastrointestinal Mucositis in Multiple Myeloma Patients Receiving High-Dose Melphalan for Autologous Stem Cell Transplantation: A Systematic Review

Comparative Outcomes of CAR-T Versus Bispecific T-Cell Engager Therapy in Relapsed/Refractory Multiple Myeloma: A TriNetX Network Analysis

Infectious Morbidity with Bispecific T Cell Engager Antibody Therapy in Relapsed/Refractory Multiple Myeloma: A Systematic Synthesis Revealing a Preventable Survival Gap

Disparities in ASCT and CAR-T Access in Multiple Myeloma: Evidence from Real-World Studies in the Era of Novel Therapies

Smoldering Multiple Myeloma With High-Risk Cytogenetics Unmasked in a Young Patient With Seronegative Systemic Sclerosis and Severe Pulmonary Arterial Hypertension

Early Intervention vs Observation in High-Risk Smoldering Multiple Myeloma: Pooled Evidence From Randomized Trials and Real-World Cohorts

The Shifting Cause-of-Death Landscape in Multiple Myeloma During the Daratumumab Era: A Race- and Sex-Stratified Competing Risk Analysis of 91768 SEER Patients